US Patent Issued to Bristol-Myers Squibb on Nov. 25 for "Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody" (New Jersey, Pennsylvania Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,917, issued on Nov. 25, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody" was invented by Sabine Maier (Lawrenceville, N.J.), Abderrahim Oukessou (Skillman, N.J.), Nicholas Allan Botwood (Princeton, N.J.), Kelly L. Covello (Philadelphia), Michael V. Mandola (Williamstown, N.J.) and Stephen R. Lane (Doylestown, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), co...